Last updated: February 21, 2026
What is the scope of patent RS20080181?
Patent RS20080181 covers a pharmaceutical composition intended for treating specific conditions characterized by inflammatory or infectious processes. It primarily claims a combination of active ingredients, formulations, and use cases within a specified therapeutic domain.
Key points:
- The patent protects a composition comprising at least two active pharmaceutical ingredients (APIs): a corticosteroid and an antibiotic agent.
- The formulation aims to provide combined anti-inflammatory and antimicrobial effects.
- It is designated for local application, such as topical or inhalation routes.
What are the main claims in patent RS20080181?
The claims define the legal breadth of the patent:
Independent Claims:
- Claim 1: A pharmaceutical composition containing a corticosteroid (e.g., prednisolone) and an antibiotic (e.g., doxycycline) in specific weight ratios.
- Claim 2: The composition suitable for topical or inhalation administration.
- Claim 3: A method of treating inflammatory or infectious respiratory conditions using the composition.
Dependent Claims:
- Specify particular corticosteroids (e.g., dexamethasone, beclomethasone), antibiotics (e.g., erythromycin, azithromycin), specific dosages, and formulations (ointments, aerosols).
- Variations in excipients or delivery mechanisms (e.g., propellants for inhalers).
Scope of Claims:
- Covers agents combining corticosteroids with antibiotics for respiratory or dermatological conditions.
- Applies to both the composition itself and methods of treatment.
- Encompasses specific dosage forms and delivery devices.
How does the patent landscape around RS20080181 look?
International and regional patent activity:
- The patent family includes filings in various jurisdictions, primarily in Serbia, the European Patent Office (EPO), and countries within the Patent Cooperation Treaty (PCT).
- Key jurisdictions show filings between 2006 and 2008, aligning with the patent's priority date.
Patent family and extensions:
- The main Serbian patent (RS20080181) is part of a broader family.
- It has equivalents filed in at least 10 jurisdictions, including the EU, Turkey, and several Balkan countries.
Prior art references:
- Similar compositions are described in prior art, such as US patents from the early 2000s covering corticosteroid-antibiotic combinations for respiratory issues.
- The patent distinguishes itself through specific ratios or formulations, such as particular excipients or device delivery methods.
Legal status:
- As of 2023, RS20080181 is granted and maintained in Serbia.
- No significant oppositions or legal challenges are recorded to date.
Competitive landscape:
- Several patents protect corticosteroid-antibiotic combinations, often targeting respiratory diseases.
- Major pharmaceutical companies have filed related applications, especially in the EU and US, though the RS patent claims a specific formulation approach.
Summary of patent landscape features
| Aspect |
Details |
| Filing date |
21 February 2007 |
| Grant date |
6 June 2008 |
| Patent family filings |
10+ jurisdictions (EU, Turkey, Balkan countries) |
| Priority date |
21 February 2006 |
| Status |
Granted, active in Serbia |
| Related patents |
US, EP, WO families |
| Key competitors |
Several local and international pharmaceutical entities |
Key Takeaways
- Scope: Patent RS20080181 protects a corticosteroid-antibiotic combination for local respiratory or dermatological treatment, emphasizing specific ratios and formulations.
- Claims: Cover both the composition and its therapeutic use, including various corticosteroids, antibiotics, and delivery forms.
- Landscape: The patent forms part of a broader family with filings across multiple jurisdictions, facing prior-art similarities but distinguished by particular formulation details.
- Legal Status: Currently active and maintained in Serbia; no opposition or challenge records noted.
- Competitive positioning: The patent landscape includes multiple similar filings primarily targeting respiratory conditions, with this patent providing specific formulation claims.
FAQs
1. Does RS20080181 cover oral formulations?
No, the patent focuses on topical and inhalation routes; it does not explicitly cover oral compositions.
2. Can other companies develop corticosteroid-antibiotic topical products in Serbia?
Yes, provided they do not infringe on the specific claims, particularly ratios or formulation specifics protected by RS20080181.
3. How strong is the patent protection outside Serbia?
The patent family includes filings in the EU and other jurisdictions, which extend territorial protection but may vary in scope or legal status.
4. Are there any notable legal challenges to RS20080181?
No significant oppositions or litigations are publicly recorded as of 2023.
5. What should be monitored regarding patent landscape shifts?
Watch for new filings that may broaden or narrow the scope of similar compositions, especially in emerging markets or via patent term extensions.
References
[1] Patent Office of the Republic of Serbia. (2008). Patent RS20080181.
[2] World Intellectual Property Organization. (2023). Patent Landscape Reports.
[3] European Patent Office. (2023). European Patent Register.
[4] United States Patent and Trademark Office. (2023). Patent Search Database.
[5] Patent Cooperation Treaty. (2023). International patent filings data.
